Navigation Links
Monogram Biosciences to Present at the JMP Securities Healthcare Conference
Date:10/10/2007

SOUTH SAN FRANCISCO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Alfred G. Merriweather, Senior Vice President and Chief Financial Officer, is scheduled to present a corporate overview at the JMP Securities Healthcare Conference on Tuesday, November 13, 2007 at 11:00 a.m. (Eastern Time) at the Four Seasons Hotel in Boston, Massachusetts.

To access the live audio broadcast or the subsequent archived recording, log on to http://www.monogrambio.com and go to the investor relations section ("Investors/Media" tab) and click on the "Events & Webcasts" link provided on the sidebar menu on the page.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Contacts: Alfred G. Merriweather

Chief Financial Officer

Tel: 650 624-4576

amerriweather@monogrambio.com

Jeremiah Hall

Feinstein Kean Healthcare<
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 According to a new ... - Global Industry Analysis, Size, Share, Growth, Trends and ... USD 25.16 billion in 2013, which is expected to ... CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis and ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
(Date:8/1/2014)... Testing the mechanical properties of ... understanding embryonic development. How and why embryonic ... functionally distinct tissues is important because abnormalities can ... McDevitt, Melissa Kinney, and Rabbia Saeed worked from ... cues to control many aspects of embryo development. ...
Breaking Biology Technology:Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:8/1/2014)... The Journal of Nutrition Education and Behavior (JNEB) announces ... (GEM) awards, which were presented at the Society for ... Impact: Local to Global," in Milwaukee, Wisconsin, June 28 ... the authors of the best article and best GEM ... of the JNEB Journal Committee and Board of Editors. ...
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
... international research team co-led by a scientist at Fred ... behind the third most common form of muscular dystrophy. ... represent the latest in the team,s series of groundbreaking ... facioscapulohumeral muscular dystrophy, or FSHD., The team, co-led by ...
... geneticists sheds new light on how Facioscapulohumeral Muscular Dystrophy ... commonly known as FSHD, the devastating disease affects both ... inherited genetic disorder, yet sometimes appears spontaneously via new ... condition. "People with the condition experience progressive ...
... 2012 - Jackson Hole, Wyoming Scientists believe that ... primary genetic material, early,forms of life used RNA to ... life,rely on before RNA? The answer may be ... a hypothetical,backbone for Peptide Nucleic Acids, which have been ...
Cached Biology News:Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 3Weber State Scientists discover possible building blocks of ancient genetic systems 2
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
... provides all the materials necessary for the isolation ... antigen studies analysis. Kit Components: ... 5122) One bottle containing 220 mL of buffered ... (5X) - (Catalog No. 5113) One bottle containing ...
... CultureWell cell culture systems provide ... cultured cells for staining and ... silicone gaskets preassembled with standard ... plates. The entire system is ...
Biology Products: